HR Execs on the Move

Fyzical

www.fyzical.com

 
FYZICAL is the world`s fastest growing healthcare franchise, leading the charge to transform healthcare from one of “sick care” to “well care” by providing services focused on quality outcomes, total well-being, and prevention. FYZICAL provides business instruments allowing you to run your business more successfully and more profitably, immediately. Using a Nobel Prize winning formula, elite PTs, medical professionals, and business experts have created an innovative new business model which not only sets the standard for excellence in patient care, but also allows you to become the dominant provider of health care services in your community and secure a successful ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.fyzical.com
  • 505 S Orange Ave
    Sarasota, FL USA 34236
  • Phone: 941.444.2213

Executives

Name Title Contact Details

Similar Companies

Hallmark Youthcare

Hallmark Youthcare is a Residential Treatment Center in Richmond, VA dedicated to treating adolescents with emotional and behavioral mental health issues since 1976.

Innocoll

A specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet important healthcare challenges

South Central Manufacturing

South Central Manufacturing is a Summersville, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novacea

Novacea, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.